To The Moon

Apple's new Apple Intelligence features could prompt many users to upgrade their older models, potentially driving a major sales Supercycle.Despite higher PE ratios (34X vs. pre-pandemic 15x), Apple's

NVIDIA on Monday announced the NVIDIA Omniverse Cloud Sensor RTX, which is a set of microservices enabling physically accurate sensor simulation to aid the development of fully autonomous machines. "Omniverse Cloud Sensor RTX accelerates the creation of simulated environments by combining real-world data from videos, cameras, radar, and lidar with synthetic data," the company said. Even for scenarios with limited real-world data, the microservices can be used to simulate a broad range of activities, such as whether a robotic arm is operating correctly, an airport luggage carousel is functional, a tree branch is blocking a roadway, a factory conveyor belt is in motion, or a robot or person is nearby, NVIDIA added. Source: Press Release

NVIDIA (NASDAQ:NVDA) reported quarterly earnings of $6.12 per share which beat the analyst consensus estimate of $5.59 by 9.48 percent. The company reported quarterly sales of $26.044 billion which beat the analyst

Attention is on AI darling’s annual GTC conference next weekNvidia often uses event to announce products and expectationsJen-Hsun HuangNvidia Corp.’s annual artificial intelligence conference is just

U.S. stocks ended sharply up on Thursday, with the S&P 500 approaching record highs as AI optimism drove gains in Nvidia and other chipmakers.The S&P 500 climbed 0.88% to end the session at 4,780.94 p

NVIDIA (NASDAQ:NVDA) reported quarterly earnings of $4.02 per share which beat the analyst consensus estimate of $3.36 by 19.64 percent. This is a 593.1 percent increase over earnings of $0.58 per share from the same

TSMC investors see signs of a turnaround in sales -- and maybe profits as well.

Bagsvrd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars.Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist that is currently being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease . Uncontrolled hypertension is when a person’s blood pressure remains high despite taking two or more blood pressure-lowering treatments.“We look forward to adding ocedurenone to our pipeline as it will complement our current development programmes in cardiovascular disease and chronic kidney disease,” said Camilla Sylvest, executive vice president, Commercial Strategy & Corporate Affairs at Novo Nordisk. “This deal is closely al

The healthcare sector is a recession-proof one with these four stocks dishing out dividends.

When looking at the last decades, Advanced Micro Devices, Inc. was an unstable business with fluctuating margins and growing outstanding shares.However, AMD changed its business model during the last